IRESSA® (gefitinib tablets) contain 250 mg of gefitinib and are available as brown film-coated tablets for daily oral administration.
IRESSA is indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies.
The effectiveness of IRESSA is based on objective response rates (see CLINICAL PHARMACOLOGY Clinical Studies section). There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival.
Results from two large, controlled, randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy. Therefore, IRESSA is not indicated for use in this setting.
Media Articles Related to Iressa (Gefitinib)
ALK-positive non-small cell lung cancer: significant discrepancies between FISH and IHC results for ALK testing
Source: Lung Cancer News From Medical News Today [2014.02.26]
The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer (NSCLC). Accurate determination of ALK-positive tumors is necessary to identify patients with advanced NSCLC who are most likely to benefit from targeted therapy with an ALK inhibitor.
Added benefit of Afatinib depends on mutation status in non-small cell lung cancer
Source: Lung Cancer News From Medical News Today [2014.02.21]
Lung cancer patients with Del19 mutation benefit mostAfatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
Radiation and chemotherapies could be more effective in treating the most common and deadly of all cancers by eliminating Mcl-1
Source: Health News from Medical News Today [2014.03.07]
Researchers at the Translational Genomics Research Institute (TGen) have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments.Non-small cell lung cancer (NSCLC) makes up about 85 percent of the nearly 160,000 Americans expected to die this year from lung cancer, which by far kills more patients than any other type of cancer; accounting for more than 1 in 4 cancer deaths in the U.S. annually. The 5-year survival rate for advanced NSCLC is less than 10 percent.
Preop PET Cuts Lung Cancer Surgery
Source: MedPageToday.com - medical news plus CME for physicians [2014.03.07]
(MedPage Today) -- Routine preoperative PET imaging led to a significant reduction in unnecessary surgery for non-small cell lung cancer, a review of almost 1,000 cases showed.
OncoBriefs: Lung Trial Ended, Gene Test Helpful
Source: MedPage Today Gastroenterology [2014.03.04]
(MedPage Today) -- The addition of one targeted agent to another did not improve survival in non-small cell lung cancer, and a genetic test for prostate cancer affected patients' treatment plans, two new studies showed.
Published Studies Related to Iressa (Gefitinib)
Gefitinib versus placebo as maintenance therapy in patients with locally advanced
or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre,
double-blind randomised phase 3 trial. 
setting... INTERPRETATION: Maintenance treatment with gefitinib significantly prolonged
Afatinib versus placebo for patients with advanced, metastatic non-small-cell
lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines
of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. 
tyrosine-kinase inhibitors... INTERPRETATION: Although we recorded no benefit in terms of overall survival with
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). [2011.07.20]
PURPOSE: The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with advanced pulmonary adenocarcinoma were published previously. This report presents overall survival (OS) and efficacy according to epidermal growth factor receptor (EGFR) biomarker status... CONCLUSION: EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel. The predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis). Treatment-related differences observed for PFS in the EGFR mutation-positive subgroup were not apparent for OS. OS results were likely confounded by the high proportion of patients crossing over to the alternative treatment.
A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. [2011.06]
BACKGROUND: Tegafur/uracil (UFT) is suitable for metronomic chemotherapy because of its underlying antiangiogenesis mechanism. This study aimed to assess the efficacy of adding daily oral UFT to gefitinib treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy... CONCLUSION: Gefitinib plus UFT treatment had better PFS than gefitinib alone treatment. Gefitinib is effective in patients with EGFR mutations, and the addition of UFT treatment produced better PFS in these patients with mutations.
Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. [2011.05]
PURPOSE: A meta-analysis of randomized controlled trials was performed to compare the efficacy, quality of life (QOL), symptom improvement and toxicities of gefitinib with docetaxel in previously treated advanced non-small-cell lung cancer... CONCLUSIONS: In conclusion, although similar OS and PFS, gefitinib showed an advantage over docetaxel in terms of objective response rate, QOL and tolerability. Therefore, gefitinib is an important and valid treatment option for previously treated advanced non-small-cell lung cancer patients.
Clinical Trials Related to Iressa (Gefitinib)
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer [Active, not recruiting]
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia [Active, not recruiting]
The purpose of this study is to determine how effective, and to what extent, Iressa is in the
treatment of acute myelogenous leukemia.
Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment [Active, not recruiting]
The purpose of this study is to provide gefitinib treatment to patients who, on completion or
closure of other gefitinib clinical studies, were either receiving placebo treatment, or are
continuing on the same dose and regimen of gefitinib established in their preceding study,
for as long as the patients continue to derive benefit.
Open-Label Extension of Other SZ1839 (Iressa) Trials [Completed]
A trial to assess patients who have been treated with Iressa in a previous clinical trial and
may benefit from continued treatment with Iressa.
First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia [Active, not recruiting]
The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet
chemotherapy given as first line treatment in terms of progression free survival in selected
Reports of Suspected Iressa (Gefitinib) Side Effects
Cystitis Haemorrhagic (7),
Interstitial Lung Disease (7),
Liver Disorder (6),
Pleural Effusion (6), more >>